Elevation of PTEN protein levels by PRL2 inhibition has been shown in the current study to prolong the time necessary for development of leukemogenesis and the progression of an AML phenotype by downregulating the AKT/mTOR signaling. The gene discussed is PTEN; the disease is acute myeloid leukemia.